Why the study?
Expatriates in Kuwait face restricted access to public healthcare and lower income than citizens, prompting an examination of differences in CKD characteristics and management between the two groups.
Does restricted healthcare access in expatriates with CKD lead to worse metabolic control and management compared to citizens?
Does restricted healthcare access in expatriates with CKD lead to worse metabolic control and management compared to citizens?
Expatriates with CKD in Kuwait have worse blood pressure and glycemic control compared to citizens, highlighting the negative impact of restricted healthcare access on chronic disease management.
Answers are grounded in this paper and cite their sources.
Expatriates show worse BP, glycemic, and lipid control in CKD 3–5 ND; leaves open whether access barriers drive outcomes and should not yet change practice.
Introduction Kuwait has a large expatriate community who experience both restricted access to public health services and lower income than Kuwaiti citizens. Given these conditions, we examined differences in characteristics and management of chronic kidney disease (CKD) between Kuwaitis and expatriates. Methods Clinical and laboratory data for adult CKD Stages 3–5 not on dialysis (CKD 3–5 ND) patients with native kidneys attending nephrology clinics in all Ministry of Health hospitals collected from January 1, 2022, to December 31, 2022. Cohort was then divided into Kuwaiti patients and expatriates patients for comparison. Results We collected data from 2,610 patients (eGFR: 30.8 ml/min/1.73m 2 ; age: 62.6 years; males: 56.7%; Kuwaitis: 62.1%). Kuwaitis were older (63.94 vs. 60.3 years, p < 0.001), with lower mean eGFR (30.4 vs. 31.5 ml/min/1.73m 2 , p = 0.052) than non-Kuwaitis, however, Kuwaitis had lower mean blood pressure (137.2/76.5 vs. 139.1/78.9 mmHg, p = 0.006), lower HbA1c in diabetics (7.59 vs. 7.82%, p = 0.010), and better lipid profile despite higher body mass indexes (29.6 vs. 28.9 kg/m 2 , p = 0.002). Both groups had high diabetes mellitus and hypertension rates. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were used in only 22.6% and renin-angiotensin-aldosterone system inhibitors (RAASi) in only 46.2%. Conclusion CKD 3–5 ND is caused by diabetes mellitus in 56.6% of cases, and the majority have hypertension. In our study, non-Kuwaitis had higher eGFR; however, restricted public healthcare access and lower income can lead to an unhealthy diet and suboptimal care, which may cause higher blood pressure, higher HbA1c, and a higher dyslipidemia rate. RAASi and SGLT2i utilization must increase to combat CKD, and antihypertensive selection must improve.
No takes yet. Share an insight, caveat, or question.
AlSahow et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: